BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -
AMPHOTEC, also known as amphotericin B colloidal dispersion or ABCD is being developed by SEQUUS Pharmaceuticals, Inc. (Nasdaq: SEQU) to treat progressive and potentially fatal systemic fungal infections. Data derived from this retrospective analysis need to be confirmed in randomized, prospective comparative trials.
A total of 149 patients with blood cultures positive for Candida were treated with AMPHOTEC during a course of five clinical trials. All patients had either failed standard amphotericin B therapy or had kidney toxicity due to amphotericin B or other causes which precluded therapy with amphotericin B and, thus, were considered refractory to standard therapy. Of these patients, a total of 72 were evaluable for efficacy (defined as having received seven doses of AMPHOTEC within the first ten days of entering the trial and no concurrent systemic antifungal therapy).
Nineteen of the 72 evaluable patients had disseminated Candidal infection, while 53 had candidemia only. The response rate in those with candidemia only was 69.8 percent (37/53), including 35 complete responses and two partial responses, while the response rate in patients with dissemination of the Candida infection was 26.3 percent (5/19), including three complete and one partial responses. Based on measurement of serum creatinine levels, there was no evidence of nephrotoxicity related to the study drug.
AMPHOTEC, marketed as AMPHOCIL(TM) outside the U.S., is approved for use in 16 countries. A New Drug Application for this product is under review by the U.S. Food and Drug Administration.
Established in 1981 and headquartered in Menlo Park, Calif. (with offices in London, England), SEQUUS is developing proprietary pharmaceutical products for the treatment of cancer and other life-threatening diseases.
CONTACT: SEQUUS Pharmaceuticals, Inc., Menlo Park I. Craig Henderson, M.D., Chairman and CEO Scott Minick, President and COO Donald J. Stewart, VP, Finance and Treasurer 415/323-9011 or Ogilvy Adams & Rinehart (Media Inquiries) Timothy Sipols, 212/880-5251 or Burns McClellan (Investor Inquiries) John Nugent, 212/505-1919
Copyright (c) 1996/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
960919
BW960914
Copyright © 1996 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .